pharmacokinetics of glp-1 receptor agonists and the kidney: from physiology to pharmacology and outcomes in diabetes Pharmacokinetics of a long-acting GLP-1
Description
Type 2 Diabetes Mellitus (T2DM) is one of the most common metabolic disorders worldwide
Partly through these actions, GLP-1 receptor agonism was shown to reduce cardiovascular disease (CVD) in people with T2D with previous CVD or at high-risk thereof
Ginfortprovides a natural solution to mitigate these issues
#glp1 #diabetes #medication #T2DM | 28 comments on LinkedIn
Could it be because Indian physicians are conservative when it comes to prescribing newer drugs
Understanding these conflicts helps ensure safe, successful treatment with semaglutide or tirzepatide
